With active pharmaceutical ingredient sales of $1,460m (€960.8m) in
2007 and a portfolio of more than 250 compounds, Teva
Pharmaceutical Industries is by a long stretch the dominant
supplier in the global API market.
A UK chemicals plant has become the latest casualty of
GlaxoSmithKline's (GSK's) pledge to make the business leaner with
the help of outsourcing and offshoring.
Jubilant Organosys, India's largest custom research and
manufacturing services (CRAMS) provider, has scored new contracts
to the tune of $92m for the year thus far as its business continues
to gather momentum.
With increasing pressures on pharma pipelines leading to greater
interest in compound licensing, firms can be caught out by failing
to give scalability issues due attention, according to Joseph
D'Antuono speaking at last week's...
Lonza has revealed a profit hike for the full year of 2007,
reflecting the fruit of its "revised growth strategies"
across its business units, said the firm, which also announced its
"innovations" for future growth...
Roche today announced a handful of new charitable technology
transfer agreements with manufacturers in Africa and Asia, allowing
local production of generic HIV drugs.
PharmEng's subsidiary Keata Pharma is the new owner of Pfizer's
manufacturing facility in Arnprior, Canada, which the drug giant
has been trying to pass on for over a year.
UK-based William Ransom & Son has a shaky future ahead
following a disappointing and unacceptable six-month financial
report, compounded by a suspension of the companys manufacturing
license.
Bristol-Myers Squibb (BMS) has finally detailed its plans to trim
the fat and save cash, months after first revealing that big
changes would be on the cards.
Pfizer is looking to Asia for both R&D and manufacturing
outsourcing and to help it cut costs in a bid to mitigate the
effects of patent expiries and competition from generic drugs.
Contract pharmaceutical development company Azopharma has carved
out its drug delivery segment into a new company, APIcross Drug
Delivery Technologies.
NPIL Pharma last week told workers at its former Pfizer plant in
Morpeth, UK that the company is considering hiving off jobs in a
bid to maintain the site's viability.
The race is on between cervical cancer vaccines Gardasil and
Cervarix as they begin to battle it out to win a more than £100m a
year supply contract with the UK Department of Health.
Denmark-based Bavarian Nordic has received an advance payment of
$50m (€35.4m) from the US Government for meeting milestones in one
of its smallpox vaccine supply contracts.
In the latest phase of growth at chemical firm SAFC's flagship high
potency active pharmaceutical ingredients (HPAPIs) facility in
Madison, Wisconsin, the site will be treated to another
multi-million dollar expansion and new...
Lonza's $200m (€147m) investment in China is continuing to shape up
as the firm announced its new small-scale exclusive synthesis
manufacturing plant will be up and running next month.
GlaxoSmithKline (GSK) and Merck Sharp & Dohme (MSD) have made
further moves in their plans to boost their presence in Singapore,
a region growing in popularity for biopharmaceutical research and
manufacture.
Australian drug delivery specialist Acrux has reported positive
results in Phase II trials of its innovative under-arm lotion
formulation for testosterone replacement therapy.
Procter & Gamble (P&G) has announced its intention to
outsource the active pharmaceutical ingredient (API) R&D and
manufacturing work undertaken at one of its US factories, with
resultant closure of the site and job losses.
Pfizer is to plough $300m (€226m) into South Korean research and development over the next five years, while it's CEO is planning to visit North Korea tomorrow.
Analysing the images from protein separation experiments, such as
2D gel electrophoresis (2DGE), is not only time consuming but can
often miss 'hits' and give false positives. But it doesn't have to
be that way, according...
UK biotech firm Acambis has decided to bring the manufacturing of
its soon to be approved smallpox vaccine in-house while its
agreement with contract manufacturer Baxter comes to an end.
A non-invasive technique that uses hair plucked from cancer
patients to guide the development of new chemotherapy drugs has
attracted the attention of UK pharma giant AstraZeneca.
Anglo-German firm Evotec is taking its fragment-based drug
discovery (FBDD) services a step further with the launch today of a
new innovation centre for FBDD.
Swiss contract manufacturer Lonza has decided to merge its US
microbial biopharma business activities in a single location, three
months after buying Cambrex's biopharma unit.
Outsourced pharmaceutical R&D spending is set to increase
at twice the expected rate of general R&D expenditure
for the next five years, according to new research published this
week.
In this week's review of activity within the preclinical research
services arena, new deals have emerged involving Gene Bridges,
Panacos Pharmaceuticals, and GenScript.
Lonza is betting on the growth of antibody-drug conjugates as the
way-of-the-future cancer treatments by moving to large scale
production of the emerging drug class by 2008.
Technology and services provider Althea Technologies has stepped
closer to a significant increase in manufacturing capacity as it
announces the completion of the first phase of construction at its
new San Diego facility.
Roche gave an update on its manufacturing of influenza drug Tamiflu
(oseltamivir) today, saying that while it had reached its target
capacity of 400 million doses a year, demand is running much lower.
Indian biotech firm Biocon is planning to boost its contract
research business as global pharma companies are increasingly
looking to outsource R&D to India, according to media reports.
A highly-acquisitive and research-intensive year has left drug
discovery services provider Galapagos further in the red at the end
of its 2006 financial year, although sales soared.
Shire Pharmaceuticals' plans to buy New River Pharmaceuticals will
eventually affect a contract manufacturing arrangement with Albany
Molecular Research (AMR).
Solvents are defined as organic chemicals that are used to dissolve components. They are used during the manufacture of drug substances and can also potentially...
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...